Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CTKB

SellSinker

Cytek Biosciences, Inc. · Healthcare · United States · $608M · Avg Vol: $4M/d

32
StockRank
Get insider-trade alerts
Q
39
V
37
M
47
P/E (TTM)
ROE
-23.0%
D/E
0.1x
Dividend %

COMPANY DESCRIPTION

Cytek Biosciences, Inc. develops and markets proprietary flow cytometry solutions, including instruments, reagents, and software, for cell analysis in research and clinical settings. Its Full Spectrum Profiling (FSP™) technology offers superior multi-parametric analysis with enhanced sensitivity and resolution compared to conventional cytometers, creating a technological advantage. Cytek is a rapidly growing player, disrupting traditional technologies with its innovative platform for deeper cell insights.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue164.0M193.0M200.5M201.5M7.1%206.7M209.4M223.2M5.3%
EPS0.02-0.09-0.05-0.52-0.63
Shares135.4M130.7M129.2M128.6M-5.0%130.0M
Debt18.1M14.1M17.0M23.7M9.5%26.5M
Equity425.3M393.1M395.7M341.7M-7.0%
Op CF-12.2M5.3M25.4M-4.7M380.6%-6.0M
Inv CF-55.9M-93.9M-83.0M10.1M
Fin CF5.5M-41.8M-15.8M-13.4M
Loading 1Y...
PRICE (1Y)+8.0%
4.164.344.524.714.89Jul 29Aug 19Sep 9
SMA 50SMA 200

Close
$4.73
RSI (14)
51.1
52W High
$6.18
From 52W High
0.8%

SCORE BREAKDOWN

Quality
39
ROIC
-10.6%34.4
ROE
-23.0%28.9
GP/Assets
23.2%51.0
Op. Margin
-29.5%23.1
FCF/Assets
n/mN/A
Piotroski
431.0
Int. Cover
-50.0x5.9
D/E Ratio
0.08x64.7
Current Ratio
4.48x68.8
Value
37
P/E (TTM)
N/A
EV/EBITDA
-9.4x25.0
P/FCF
n/mN/A
P/B
1.9x65.0
P/S
3.0x57.1
Div Yield
N/A
Momentum
47
52W High %
77%61.2
RS 6M
-1%63.7
SMA 50/200
0.99x54.1
EPS Rev 4W
-65.0%0.5
EPS Rev 12W
-63.2%1.0
EPS Improve
+111%76.7
Q Growth
N/A

FUNDAMENTALS

Market Cap
$608M
P/E (Forward)
67.1x
Gross Margin
51.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTKB are excluded.

TickerCompanyMkt CapStockRankSignal
CTKBCytek Biosciences, Inc.(you)$608M32Sell
NPCENeuroPace, Inc.$495M32Sell
SENSSenseonics Holdings, Inc.$493M29Sell
CERSCerus Corporation$534M37Hold
KIDSOrthoPediatrics Corp.$617M41Hold
BBNXBeta Bionics, Inc.$887M27Sell
QDELQuidelOrtho Corporation$1.0B29Sell
CBLLCeriBell, Inc.$911M27Sell
AHCOAdaptHealth Corp.$772M41Hold
OFIXOrthofix Medical Inc.$392M27Sell

Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%

Cytek Biosciences, Inc. (CTKB): Stock Score Summary

Cytek Biosciences, Inc. (CTKB) has a MoatMap StockRank of 32/100 based on Quality (39/100), Value (37/100), and Momentum (47/100) factor scores. The current signal is SELL.

Cytek Biosciences, Inc. develops and markets proprietary flow cytometry solutions, including instruments, reagents, and software, for cell analysis in research and clinical settings. Its Full Spectrum Profiling (FSP™) technology offers superior multi-parametric analysis with enhanced sensitivity and resolution compared to conventional cytometers, creating a technological advantage. Cytek is a rapidly growing player, disrupting traditional technologies with its innovative platform for deeper cell insights.

Key Financial Metrics

Price$4.73
Market Cap$608M
P/E (Forward)67.14
Price/Book1.90
Return on Equity-23.0%
Return on Invested Capital-10.6%
Debt/Equity0.08x
Gross Margin51.9%
Operating Margin-29.5%
Revenue Growth5.6%
Free Cash Flow$9M

Cytek Biosciences, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Cytek Biosciences, Inc.’s (CTKB) StockRank?
MoatMap’s StockRank for Cytek Biosciences, Inc. (CTKB) is 32/100, with a Sell signal. It is a composite of Quality (39), Value (37), and Momentum (47) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Cytek Biosciences, Inc. have an economic moat?
Cytek Biosciences, Inc. (CTKB) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cytek Biosciences, Inc. a buy, hold, or sell?
MoatMap’s current signal for Cytek Biosciences, Inc. (CTKB) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Cytek Biosciences, Inc. in?
Cytek Biosciences, Inc. (CTKB) operates in the Healthcare sector, specifically the Medical Devices industry (United States).